Inhalation Sciences’ primary product

PreciseInhale® is an advanced laboratory system that lets scientists measure how inhaled particles act in our lungs and affect our health. Today’s standard technologies for this are largely unchanged since the 1950’s, often producing variable, unreliable data. Despite the lung’s impressive ability to get drugs into the body faster and more efficiently than other therapies, developing new inhaled medicines has been held back by poor data that fails to correlate early lab results and later clinical results – a failure that can cost pharma scientists millions in lost investment.

​

PreciseInhale® changes all that. It delivers results with a proven high correlation between laboratory and human testing – paving the way for more cost-efficient medicines for rapidly-rising global killers like asthma and COPD (chronic obstructive pulmonary disease) - and a new generation of inhaled drugs in broader therapeutic areas, like migraine, impotence, diabetes and influenza. PreciseInhale® is built in modules. It can be tailored closely to the customer’s specific needs. It has been purchased by both pharma scientists developing new treatments, and environmental researchers testing the effects of airborne particle pollutants.